Statins enhance trastuzumab deruxtecan efficacy: preclinical synergy in HER2-negative models and clinical benefit in HER2-positive metastatic breast cancer [0.03%]
他汀类药物可增强T-DXd的疗效：HER2阴性模型中的体内协同作用以及HER2阳性转移性乳腺癌患者中的临床益处
Taha Koray Sahin,Cemal Orhan,Ibrahim Hanifi Ozercan et al.
Taha Koray Sahin et al.
Trastuzumab deruxtecan (T-DXd) has demonstrated significant efficacy in metastatic breast cancer (mBC) with varying HER2 expression. Statins have been shown to increase HER2 membrane localization and stability, potentially enhancing respons...
Radiotherapy synergizes with CD24 blockade to initiate macrophage-driven systemic antitumor immunity in non-small cell lung cancer [0.03%]
放射治疗与CD24阻断协同启动巨噬细胞介导的小细胞肺癌全身抗肿瘤免疫反应
Gongjun Wang,Shuo Yuan,Fuhao Xu et al.
Gongjun Wang et al.
Background: Radiotherapy (RT) has been shown to elicit antitumor immune responses, yet it rarely induces durable systemic immunity. The identification of immune checkpoints that constrain RT-induced immune activation rema...
Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy [0.03%]
靶向ONC病毒新辅助治疗联合PD-1抑制剂用于肢端黑色素瘤长期生存的临床前研究：STING在耐药和潜在疗法中的作用
Qian Zhao,Yu Du,Lifeng Li et al.
Qian Zhao et al.
Background: Our phase Ib neoadjuvant trial demonstrated that oncolytic virus (OV) combined with PD-1 blockade achieved a 77.8% pathological response rate and 81.5% 2-year relapse-free survival in patients with acral melan...
Bidirectional crosstalk between cancer-associated fibroblasts and tumor immunity: shaping the microenvironment and response to immune checkpoint therapy [0.03%]
癌相关的成纤维细胞与肿瘤免疫之间的双向串扰：塑造微环境和影响对免疫点抑制疗法的反应
Shiqing Wang,Di Wang,Yipeng Zhou et al.
Shiqing Wang et al.
Immune checkpoint therapy (ICT) has revolutionized cancer treatment by restoring cytotoxic T-cell activity, yet primary and acquired resistance remain pervasive. Increasing evidence reveals that such resistance is not dictated solely by tum...
Emerging therapeutic advances for immune thrombocytopenia: highlights from selected early‑phase and pivotal trials at the 2025 ASH annual meeting [0.03%]
免疫性血小板减少症的新兴治疗进展：2025年ASH年会精选早期和关键试验亮点
Linyu Cao,Zhe Wang,Qian Xiang
Linyu Cao
This letter highlights emerging immune-targeted therapies for immune thrombocytopenia (ITP) presented at the 2025 ASH Annual Meeting. We summarize pivotal data, including the Phase III VAYHIT2 trial of Ianalumab, alongside novel early-phase...
Preclinical and clinical studies on CAR-NK cell therapy: latest update from 2025 ASH Annual Meeting [0.03%]
2025年ASH年会CAR-NK细胞治疗的最新研究进展
Hanxi Luo,Yiyang Ding,Xiangyu Zhao
Hanxi Luo
Chimeric antigen receptor-engineered natural killer (CAR-NK) cells are emerging as an off-the-shelf immunotherapy for hematologic malignancies, supported by early clinical data and a favorable safety profile. Compared with CAR-T therapy, CA...
Hierarchies of resistance to DNA damage response inhibitors: from pathway restoration to replication stress tolerance [0.03%]
DNA修复抑制剂的耐药层级：从修复通路重建至复制压力耐受性
Valentina Morgera,Antonia Feola,Antonella Romano et al.
Valentina Morgera et al.
DNA damage response (DDR) inhibitors have reshaped precision oncology by exploiting tumor-specific vulnerabilities in genome maintenance and replication stress control. The clinical success of poly(ADP-ribose) polymerase (PARP) inhibitors-p...
Inhibition of protein kinase CK2 remodels the tumor immune microenvironment and sensitizes lung cancer to PD-L1 blockade [0.03%]
蛋白激酶CK2抑制可重塑肿瘤免疫微环境并使肺癌对PD-L1阻断敏感化
Sijia Zhang,Lihua Luo,Yangang Qu et al.
Sijia Zhang et al.
Background: Protein kinase CK2 is a pleiotropic oncogenic serine/threonine kinase implicated in multiple cancer-associated signaling pathways. However, its role in shaping the tumor immune microenvironment (TIME) and regu...
ISX-TWIST1 reprograms CD47-inflammasome signaling to reshape the immune microenvironment in liver cancer [0.03%]
ISX-TWIST1 通过重新编程 CD47-炎性小体信号来重塑肝癌免疫微环境
Li-Ting Wang,Ming-Hong Lin,Yi-Chuan Li et al.
Li-Ting Wang et al.
Immunotherapies have shown promise effectiveness in cancer treatment, yet the complex tumor microenvironment poses challenges to their efficacy. The interaction between immune checkpoints in malignant and immune cells is crucial for cancer ...
Combining circulating tumor cell and circulating cell-free DNA analyses broadens clinical applicability of liquid biopsy in high grade serous tubo-ovarian carcinoma [0.03%]
循环肿瘤细胞和循环游离DNA分析的结合可提高液态活检在高级别浆液性输卵管卵巢癌中的临床应用范围
Beatrice Cavina,Simona Corrà,Camelia Alexandra Coadă et al.
Beatrice Cavina et al.
Liquid biopsy is a promising strategy for detecting and monitoring neoplastic diseases, with circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) being the most common objects of investigation. Studies are mainly focusing on the...